Description
Instructions
It is anticipated that the initial discussion post should be in the range of 250-300 words. Response posts to peers have no minimum word requirement but must demonstrate topic knowledge and scholarly engagement with peers. Substantive content is imperative for all posts. All discussion prompt elements for the topic must be addressed. Please proofread your response carefully for grammar and spelling. Do not upload any attachments unless specified in the instructions. All posts should be supported by a minimum of one scholarly resource, ideally within the last 5 years. Journals and websites must be cited appropriately. Citations and references must adhere to APA format.
I have done the research for you. Answers should be in the links provided. Keep it short but concise
Discussion Prompt
- Discuss the use of conventional mood stabilizers in the treatment of bipolar depression. For this discussion, list at least two medications that have an FDA approval for bipolar depression. What are the risks/benefits of using these medications to treat bipolar depression? > (Seroquel and Latuda) https://pubmed.ncbi.nlm.nih.gov/24237641/
- Which mood stabilizers are preferred for use in the geriatric population? (Valproic acid and Lithium) https://www.nimh.nih.gov/news/science-news/2017/mood-stabilizing-medications-an-effective-option-for-older-adults-with-bipolar-disorder.shtml
- Discuss topiramate. What is it used for (in psychiatry)? For this discussion include any associated monitoring, testing, or major side effects. https://www.psychiatrictimes.com/view/topiramate-bipolar-disorder-comorbidities-the-myths-evidence
- Which mood stabilizers are FDA approved in children and adolescents for psychiatric disorders? https://www.adhdmoodbehaviorcenter.com/bipolar-disorder-in-children-and-teens/ and https://pubmed.ncbi.nlm.nih.gov/17696785/
- Discuss gabapentin. What is it used for (in psychiatry)? For this discussion include any associated monitoring, testing, or major side effects. https://www.verywellmind.com/neurontin-and-off-label-use-bipolar-disorder-380400 and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732322/
